What is the price target for XLO stock?
5 analysts have analysed XLO and the average price target is 28.56 USD. This implies a price increase of 237.19% is expected in the next year compared to the current price of 8.47.
XILIO THERAPEUTICS INC (XLO) Forecast, Price Target & Analyst Ratings
NASDAQ:XLO • US98422T2096
Current stock price
8.47 USD
-0.13 (-1.51%)
At close:
8.7008 USD
+0.23 (+2.72%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for XILIO THERAPEUTICS INC (XLO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.67
- Revenue Estimate
- 8.605M
Price Target Details & History
Consensus Price Target and Range
Mean target
$28.56
Upside
+ 237.19%
From current price of $8.47 to mean target of $28.56, Based on 5 analyst forecasts
Low
$28.28
Median
$28.56
High
$29.40
Price Target Revisions
1 Month
1,300.00%
3 Months
1,300.00%
Price Target Summary
5 Wall Street analysts provided a forecast for the next 12 months for XLO. The average price target is 28.56 USD. This implies a price increase of 237.19% is expected in the next year compared to the current price of 8.47.
The average price target has been revised upward by 1300% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.00%
XLO was analyzed by 5 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about XLO.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed XLO. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-06 | Leerink Partners | Initiate | Outperform |
| 2024-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-05-30 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Overweight |
| 2022-12-21 | Chardan Capital | Initiate | Buy |
| 2022-11-10 | Raymond James | Maintains | Outperform |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-01-10 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-16 | Cowen & Co. | Initiate | Outperform |
| 2021-11-16 | Raymond James | Initiate | Outperform |
| 2021-11-16 | Morgan Stanley | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 7, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.67
- Revenue Estimate
- 8.605M
- Revenue Q2Q
- 193.69%
- EPS Q2Q
- 73.55%
- Number of Analysts
- 2
Next Earnings Revisions
Revenue (1 Month)
23.48%
Revenue (3 Months)
23.48%
EPS (1 Month)
66.33%
EPS (3 Months)
-371.43%
Next Earnings Summary
XLO is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.67 USD and the consensus revenue estimate is 8.61M USD.
The next earnings revenue estimate has been revised upward by 23.48% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.344M | 43.766M 589.88% | 27.583M -36.98% | 74.134M 168.77% | 8.171M -88.98% | 4.414M -45.98% | 2.565M -41.89% | 1.515M -40.94% | 55.146M 3,540.00% | 14.948M -72.89% | ||
| EBITDA YoY % growth | -77.233M 11.53% | -58.001M 24.90% | -40.441M 30.28% | -57.57M -42.36% | -42.864M 25.54% | -38.168M 10.96% | -14.726M 61.42% | 115.85M 886.71% | N/A | N/A | N/A | |
| EBIT YoY % growth | -79.133M 11.24% | -59.645M 24.63% | -41.982M 29.61% | -28.28M 32.64% | -79.891M -182.50% | -237.35M -197.09% | -296.94M -25.11% | -336.33M -13.27% | N/A | N/A | N/A | |
| Operating Margin | N/A | -940.18% | -95.92% | -102.53% | -107.77% | -2,904.79% | -6,727.23% | -13,112.28% | N/A | N/A | N/A | |
| EPS YoY % growth | -38.92 13.66% | -17.36 55.40% | -4.03 76.76% | -2.55 36.91% | -6.79 -166.67% | -5.66 16.67% | 0.37 106.52% | 1.10 198.63% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.67 73.55% | -1.98 11.63% | -2.12 -2,425.00% | 3.54 336.42% |
| Revenue Q2Q % growth | 8.605M 193.69% | 6.06M -25.04% | 5.252M -72.45% | 64.236M 369.36% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.766M -21.05% | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-11.92%
EPS Next 5 Year
17.85%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-43.83%
Revenue Next 5 Year
-43.89%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
4.85%
EBIT Next 5 Year
35.52%
XILIO THERAPEUTICS INC / XLO Forecast FAQ
Can you provide the upcoming earnings date for XILIO THERAPEUTICS INC?
XILIO THERAPEUTICS INC (XLO) will report earnings on 2026-05-07.
What are the consensus estimates for XLO stock next earnings?
The consensus EPS estimate for the next earnings of XILIO THERAPEUTICS INC (XLO) is -0.67 USD and the consensus revenue estimate is 8.61M USD.
What is the number of analysts for XLO stock?
The number of analysts covering XILIO THERAPEUTICS INC (XLO) is 5.